Company: BNBX
Filing Date: 2025-10-30
Form Type: S-1
Source: 0001104659-25-103871
Chunk: 125

Company: BNB PLUS CORP.
Filing Date: 2025-10-30
Form: S-1
Chunk 125
---
 The Limited. Ms. Schmalz Shaheen started her senior management career at Revlon with responsibility for new product development for brands including Borghese, Ultima II and Prestige fragrances. She is an active member of Cosmetic Executive Women. She earned a bachelor’s degree in psychology from Georgian Court University and serves on their Board of Trustees.

Director Independence

The Board has determined that each of our directors other than Ms. Murrah — consisting of Robert B. Catell, Joseph D. Ceccoli, Yacov A. Shamash and Elizabeth M. Schmalz Shaheen — are “independent” as defined by the listing standards of Nasdaq, constituting a majority of independent directors on our Board as required by the rules of Nasdaq. The Board considers in its evaluation of independence whether any director has a relationship with us that would interfere with the exercise of independent judgment in carrying out his or her responsibilities of a director.

<div align='center'>72</div>

Board of Directors Leadership Structure and Role in Risk Oversight Our Board does not have a policy on whether the same person should serve as both the Chief Executive Officer and Chairperson of the Board or, if the roles are separate, whether the Chairperson should be selected from the non-employee directors or should be an employee. Our risk management program is overseen by our Chief Executive Officer. Material risks are identified and prioritized by management, and each prioritized risk is referred to a Board committee or the full Board for oversight. For example, strategic risks are referred to the full Board while financial risks are referred to the Audit Committee. The Board regularly reviews information regarding our liquidity and operations, as well as the risks associated with each. Also, the Compensation Committee periodically reviews the most important risks to our business to ensure that compensation programs do not encourage excessive risk-taking and promote our goals and objectives. Board of Directors Structure and Committee Composition In June 2008, the Board established a standing Compensation Committee and in September 2011, the Board established an Audit Committee and a Nominating Committee. Each of the committees operates under a written charter adopted by the Board. All of the committee charters are available on our web site at www.adnas.com/adnas_home/ investors/ or by writing to Applied DNA Sciences, Inc., 50 Health Sciences Drive, Stony Brook, New York 11790, c/o Investor Relations. The information found on, or accessible through, our website is not incorporated into, and does not form a part of, this prospect